Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Impact · against what's priced in

Evotec and Odyssey Therapeutics enter a strategic R&D collaboration focusing on autoimmune and inflammatory diseases. While the partnership adds potential milestone revenue for Evotec and expands Odyssey's discovery capabilities, the lack of disclosed financial terms limits the immediate valuation impact.

EVO+0.30: No priced-in read yet

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

What matters in this story

Roche says divarasib cut risk of death 44% in lung cancer trial

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

What matters in this story

Roche says divarasib cut risk of death 44% in lung cancer trial

How each ticker is affected

Connected tickers

Track these names every morning.

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Apple's Market Cap Grew From $350 Billion to $4.6 Trillion During Tim Cook's 15 Years as CEO. Here's What That Growth Curve Means for Apple's Next Chapter Under John Ternus.

Amkor Technology: Nvidia's $3 Billion Vote Of Confidence Lands On A De-Rated Stock

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

What matters in this story

Next reads from the same story arc

Roche says divarasib cut risk of death 44% in lung cancer trial

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

What matters in this story

Next reads from the same story arc

Roche says divarasib cut risk of death 44% in lung cancer trial

How each ticker is affected

Connected tickers

Track these names every morning.

Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28

Odyssey Therapeutics Highlights OD-001 Phase IIa UC Data, Sets 2027 Trial Readouts

Apple's Market Cap Grew From $350 Billion to $4.6 Trillion During Tim Cook's 15 Years as CEO. Here's What That Growth Curve Means for Apple's Next Chapter Under John Ternus.

Amkor Technology: Nvidia's $3 Billion Vote Of Confidence Lands On A De-Rated Stock